BOLT Bolt Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BOLT

Price (delayed)

$4.265

Market cap

$8.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.4

Enterprise value

$18.69M

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 23
Relative Valuation: Rel. Valuation: 28
Relative Profitability: Rel. Profitability: 39

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach ...

Highlights
The company's net income has surged by 53% YoY and by 11% QoQ
The EPS has soared by 51% YoY and by 8% from the previous quarter
The revenue has soared by 79% YoY but it fell by 16% QoQ
Bolt Biotherapeutics's gross profit has soared by 79% YoY but it has decreased by 16% from the previous quarter
The equity has plunged by 58% YoY and by 25% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://boltbio.com
Peers: NPKI NOV FTI GEOS

Key stats

What are the main financial stats of BOLT

BOLT stock price

How has the Bolt Biotherapeutics stock price performed over time
Intraday
6.36%
1 week
-1.04%
1 month
-13.84%
1 year
-23.84%
YTD
-22%
QTD
5.57%

Financial performance

How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$6.5M
Gross profit
$6.5M
Operating income
-$31.6M
Net income
-$29.58M
Gross margin
100%
Net margin
-455.1%
The revenue has soared by 79% YoY but it fell by 16% QoQ
Bolt Biotherapeutics's gross profit has soared by 79% YoY but it has decreased by 16% from the previous quarter
Bolt Biotherapeutics's operating margin has soared by 74% YoY but it has decreased by 3.6% from the previous quarter
The net margin has soared by 74% YoY but it has contracted by 4.9% from the previous quarter

Price vs fundamentals

How does BOLT's price correlate with its fundamentals

Growth

What is Bolt Biotherapeutics's growth rate over time

Valuation

What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.41
P/S
1.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.88
The EPS has soared by 51% YoY and by 8% from the previous quarter
The equity has plunged by 58% YoY and by 25% from the previous quarter
BOLT's P/B is 30% above its last 4 quarters average of 0.3 but 22% below its 5-year quarterly average of 0.5
The stock's P/S is 98% less than its 5-year quarterly average of 47.1 and 42% less than its last 4 quarters average of 1.8
The revenue has soared by 79% YoY but it fell by 16% QoQ

Efficiency

How efficient is Bolt Biotherapeutics business performance
The ROS has soared by 74% YoY but it has contracted by 4.9% from the previous quarter
Bolt Biotherapeutics's ROIC has increased by 24% YoY
Bolt Biotherapeutics's ROA has increased by 20% YoY but it has decreased by 2.3% from the previous quarter
The ROE fell by 9% QoQ and by 4.2% YoY

Dividends

What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BOLT.

Financial health

How did Bolt Biotherapeutics financials performed over time
The total assets is 70% greater than the total liabilities
The total assets has declined by 44% year-on-year and by 15% since the previous quarter
Bolt Biotherapeutics's total liabilities has decreased by 28% YoY and by 7% from the previous quarter
The debt is 13% more than the equity
BOLT's debt to equity has soared by 113% YoY and by 30% from the previous quarter
The equity has plunged by 58% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.